Publication: Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations
Open/View Files
Date
2016
Published Version
Journal Title
Journal ISSN
Volume Title
Publisher
Taylor & Francis
The Harvard community has made this article openly available. Please share how this access benefits you.
Citation
Ahronian, Leanne G., and Ryan B. Corcoran. 2016. “Effective MAPK Inhibition is critical for therapeutic responses in colorectal cancer with BRAF mutations.” Molecular & Cellular Oncology 3 (1): e1048405. doi:10.1080/23723556.2015.1048405. http://dx.doi.org/10.1080/23723556.2015.1048405.
Research Data
Abstract
ABSTRACT RAF inhibitor monotherapy is ineffective in BRAF-mutant colorectal cancer (CRC) but RAF inhibitor combinations have demonstrated improved efficacy, likely through superior suppression of MAPK signaling. The first identified mechanisms of acquired resistance to these combinations all promote MAPK reactivation, underscoring the MAPK pathway as a critical target in BRAF-mutant CRC.
Description
Other Available Sources
Keywords
Clinical trials, colorectal cancer, BRAF, BRAF inhibitor, ERK inhibitor, MAPK, resistance
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material (LAA), as set forth at Terms of Service